ARS-02(ARS-02) - 在研适应症：神经退行性疾病_专利_临床

概要

基本信息

药物类型

细胞因子

别名

靶点-

作用方式-

作用机制-

治疗领域

神经系统疾病

在研适应症

神经退行性疾病

非在研适应症-

原研机构

ARScience Biotherapeutics Inc.

在研机构

ARScience Biotherapeutics Inc.

非在研机构-

最高研发阶段临床申请

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 ARS-02 相关的临床结果

登录后查看更多信息

100 项与 ARS-02 相关的转化医学

登录后查看更多信息

100 项与 ARS-02 相关的专利（医药）

登录后查看更多信息

1

项与 ARS-02 相关的文献（医药）

2002-03-01·International Immunopharmacology2区 · 医学

Toll-like receptor 2 is at least partly involved in the antitumor activity of glycoprotein from Chlorella vulgaris

2区 · 医学

Article

作者: Tetsuya Matsuguchi ; Shoichiro Kumamoto ; Takashi Hasegawa ; Yukihiro Shoyama ; Kuniaki Tanaka ; Yasunobu Yoshikai ; Kiyoshi Noda

Toll-like receptors (TLR) are involved in innate immunity by recognizing various bacterial components. We have previously reported that an active substance of ARS-2 purified from the culture medium of Chlorella vulgaris was a glycoprotein with a molecular weight of 63,100 amu and that this glycoprotein expressed antitumor activity, with the protein moiety in ARS-2 being necessary for this antitumor activity. Here, we show that ARS-2 stimulated spleen-adherent cells from C3H/HeJ lacking functional TLR4 to produce interleukin-12 (IL-12) p40, whereas such cytokine production was significantly impaired in ARS-2-stimulated spleen-adherent cells from TLR2 knockout mice. The overexpression of mouse TLR2 (mTLR2) and mouse CD14 (mCD14) conferred the ARS-2 inducibility of nuclear factor-kappaB activation to human HEK 293 cells. These results suggest that TLR2 signaling is at least partly involved in the antitumor activity of the water-soluble antitumor glycoprotein from C. vulgaris.

100 项与 ARS-02 相关的药物交易

登录后查看更多信息